⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thiosemicarbazide SCHEMBL11517512 | 0.80 | ALDH1A1 (0.36) | — | |
| SCHEMBL11405843 | 0.71 | — | — | |
| SCHEMBL9380203 | 0.67 | — | — | |
| SCHEMBL667084 | 0.67 | — | — | |
| SCHEMBL19664286 | 0.67 | — | — | |
| SCHEMBL9380211 | 0.67 | — | — | |
| SCHEMBL3144398 | 0.67 | — | — | |
| SCHEMBL371880 | 0.67 | — | — | |
| SCHEMBL16320462 | 0.67 | — | — | |
| SCHEMBL156559 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 554 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720296-A2 | ANTISENSE OLIGONUCLEOTIDES FOR RETT SYNDROME | Baylor College of Medicine (US) | 2026-04-08 | — | — | EP | claimed |
| WO-2024249916-A2 | ANTISENSE OLIGONUCLEOTIDES FOR RETT SYNDROME | BAYLOR COLLEGE OF MEDICINE (US) | 2024-12-05 | — | — | WO | claimed |
| WO-2024175707-A1 | A SYNTHETIC OLIGONUCLEOTIDE FOR TREATING NIDOVIRALES INFECTIONS | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2024-08-29 | — | — | WO | claimed |
| US-11155857-B2 | Methods for measuring RNA translation rates | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-10-26 | — | — | US | claimed |
| US-20190177782-A1 | METHODS FOR MEASURING RNA TRANSLATION RATES | DANA-FARBER CANCER INSTITUTE, INC. | 2019-06-13 | — | — | US | claimed |
| EP-3478702-A1 | METHODS FOR MEASURING RNA TRANSLATION RATES | Dana-Farber Cancer Institute, Inc. (US) | 2019-05-08 | — | — | EP | claimed |
| CN-109476695-A | Method for determining RNA translation rate | 丹娜法伯癌症研究院 | 2019-03-15 | — | — | CN | claimed |
| WO-2018005283-A1 | METHODS FOR MEASURING RNA TRANSLATION RATES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-01-04 | — | — | WO | claimed |
| EP-4351699-B1 | SYSTEM INDUCING EXTRAVASATION BY ENERGY DELIVERY TO TISSUE | GALVANIZE THERAPEUTICS INC (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4747263-A1 | LIPID NANOPARTICLES AND USES THEREOF | University of Connecticut (US) | 2026-05-27 | — | — | EP | disclosed |
| US-20260137797-A1 | MUSCLE TARGETING COMPLEXES FOR TREATING DYSTROPHINOPATHIES | DYNE THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260132403-A2 | ANTISENSE OLIGONUCLEOTIDES FOR TARGETING PROGRANULIN | HOFFMANN-LA ROCHE INC. (US) | 2026-05-14 | — | — | US | disclosed |
| CN-122010896-A | Bicyclol derivative, pharmaceutical composition thereof, preparation method and application thereof | 中国医学科学院药物研究所 | 2026-05-12 | — | — | CN | disclosed |
| US-20260124308-A1 | OLIGONUCLEOTIDES CONJUGATED TO OLEIC ACID AND USES THEREOF | UNIV VALENCIA (ES) | 2026-05-07 | — | — | US | disclosed |
| US-7129252-B2 | Six membered amino-amide derivatives an angiogenisis inhibitors | HLB CO., LTD. (KR) | 2006-10-31 | — | — | US | disclosed |
| EP-1633712-A2 | SIX MEMBERED AMINO-AMIDE DERIVATIVES AS ANGIOGENESIS INHIBITORS | Chen, Guoqing Paul (US) | 2006-03-15 | — | — | EP | disclosed |
| WO-2005000232-A2 | SIX MEMBERED AMINO-AMIDE DERIVATIVES AS ANGIOGENESIS INHIBITORS | CHEN GUOQING PAUL (US) | 2005-01-06 | — | — | WO | disclosed |
| US-20040259916-A1 | Six membered amino-amide derivatives an angiogenisis inhibitors | HLB CO., LTD. (KR) | 2004-12-23 | — | — | US | disclosed |
| EP-0262307-A2 | Process for preparing hydroxymorpholines and morpholines | TEXACO DEVELOPMENT CORPORATION (US) | 1988-04-06 | — | — | EP | disclosed |
| US-4670557-A | Process for preparing hydroxymorpholines | TEXACO INC. (US) | 1987-06-02 | — | — | US | disclosed |